We are live on ! Find out more
AFC

Ares Financial Consulting Portfolio holdings

AUM $139M
This Fund
S&P 500
This Quarter Est. Return
+12.94%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$139M
AUM Growth
+$12.1M
Cap. Flow
+$897K
Cap. Flow %
0.64%
Top 10 Hldgs %
40.89%
Holding
1,171
New
105
Increased
235
Reduced
84
Closed
39
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HUT
1001
Hut 8
HUT
$11.6B
$1.04K ﹤0.01%
+9
New +$873
JHG
1002
DELISTED
Janus Henderson
JHG
$1.04K ﹤0.01%
20
LW icon
1003
Lamb Weston
LW
$7.2B
$1.04K ﹤0.01%
24
-12
-33% -$518
NTES icon
1004
NetEase
NTES
$82.9B
$1.02K ﹤0.01%
8
JXN icon
1005
Jackson Financial
JXN
$9B
$1.02K ﹤0.01%
10
VTS icon
1006
Vitesse Energy
VTS
$667M
$1.01K ﹤0.01%
64
SEM
1007
DELISTED
Select Medical
SEM
$1.01K ﹤0.01%
61
GRWG icon
1008
GrowGeneration
GRWG
$89.5M
$1.01K ﹤0.01%
680
LNN icon
1009
Lindsay Corp
LNN
$1.17B
$990 ﹤0.01%
8
KNSL icon
1010
Kinsale Capital Group
KNSL
$8.48B
$989 ﹤0.01%
+3
New +$965
GKOS icon
1011
Glaukos
GKOS
$10B
$978 ﹤0.01%
+7
New +$886
SYRE icon
1012
Spyre Therapeutics
SYRE
$9.1B
$977 ﹤0.01%
+11
New +$803
ACGL icon
1013
Arch Capital
ACGL
$33.8B
$971 ﹤0.01%
+10
New +$943
XPEV icon
1014
XPeng
XPEV
$11.1B
$967 ﹤0.01%
73
MSTR icon
1015
Strategy Inc
MSTR
$37.3B
$956 ﹤0.01%
11
-784
-99% -$114K
EWTX icon
1016
Edgewise Therapeutics
EWTX
$4.73B
$934 ﹤0.01%
+23
New +$793
IDYA icon
1017
IDEAYA Biosciences
IDYA
$3.5B
$932 ﹤0.01%
+25
New +$765
KBR icon
1018
KBR
KBR
$4.75B
$932 ﹤0.01%
27
ANIP icon
1019
ANI Pharmaceuticals
ANIP
$1.88B
$911 ﹤0.01%
11
ULTA icon
1020
Ulta Beauty
ULTA
$23.1B
$902 ﹤0.01%
2
VSNT
1021
Versant Media Group
VSNT
$5.57B
$902 ﹤0.01%
25
-1
-4% -$40
GTES icon
1022
Gates Industrial Corporation Ltd.
GTES
$7.28B
$895 ﹤0.01%
+32
New +$822
PAG icon
1023
Penske Automotive Group
PAG
$14.2B
$895 ﹤0.01%
5
WMG icon
1024
Warner Music
WMG
$13.6B
$893 ﹤0.01%
+33
New +$982
LBRT icon
1025
Liberty Energy
LBRT
$3.33B
$890 ﹤0.01%
34

Similar funds

Ares Financial Consulting's Q2 2026 Portfolio in Review

As of Q2 2026, Ares Financial Consulting held 1,171 positions worth $139M, up 9.5% from $127M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ares Financial Consulting's Q2 2026 filing shows 105 new, 235 increased, 84 reduced and 39 closed positions. Its largest new stake was AstraZeneca: 486 shares worth $92.2K. The largest sale was Dimensional US Core Equity Market ETF, an estimated $443K.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 10% a quarter earlier, followed by Communication Services and Industrials.

  • Ares Financial Consulting's largest Q2 2026 buy was AstraZeneca: 486 shares worth $92.2K.
  • Ares Financial Consulting added most to PIMCO 15+ Year US TIPS Index Exchange-Traded Fund in Q2 2026, an estimated $567K increase.
  • Ares Financial Consulting's biggest Q2 2026 reduction was Dimensional US Core Equity Market ETF, cutting an estimated $443K.
  • Ares Financial Consulting fully exited Vanguard FTSE All-World ex-US ETF in Q2 2026, selling an estimated $203K.
  • Ares Financial Consulting's ten largest holdings make up 41% of its $139M portfolio in Q2 2026.
  • Ares Financial Consulting opened 105 new positions and closed 39 in Q2 2026.
  • Ares Financial Consulting's portfolio value rose 9.5% quarter-over-quarter to $139M.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.